GLPwatch

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.

Dermatol Reports · 2023

Last updated 2026-06-28
JournalDermatol Reports, 2023
Citations12
Relative citation ratio2.22
NIH percentile76
Molecules dulaglutide

Abstract

Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.

Verbatim abstract via PubMed 37822982 ↗

Related research